rs4774518

Variant summary

Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_StrongPP5_Very_Strong

The NM_207581.4(DUOXA2):​c.738C>G​(p.Tyr246*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000411 in 1,603,982 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Y246Y) has been classified as Benign.

Frequency

Genomes: 𝑓 0.000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000039 ( 0 hom. )

Consequence

DUOXA2
NM_207581.4 stop_gained

Scores

1
2
4

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:7

Conservation

PhyloP100: -1.77

Publications

40 publications found
Variant links:
Genes affected
DUOXA2 (HGNC:32698): (dual oxidase maturation factor 2) This gene encodes an endoplasmic reticulum protein that is necessary for proper cellular localization and maturation of functional dual oxidase 2. Mutations in this gene have been associated with thyroid dyshormonogenesis 5.[provided by RefSeq, Feb 2010]
DUOXA1 (HGNC:26507): (dual oxidase maturation factor 1) Dual oxidases DUOX1 and DUOX2 are NADPH oxidases which are involved in hydrogen peroxide production necessary for thyroid hormonogenesis. They form a heterodimer with specific maturation factors DUOXA1 and DUOXA2, respectively, which is essential for the maturation and function of the DUOX enzyme complexes. This gene encodes the DUOX1 activator or maturation factor DUOXA1. Rat studies identified a bidirectional promoter which controls the transcription of the DUOX1 and DUOXA1 genes. This protein is cotransported to the cell surface when coexpressed with DUOX1 and is retained in the endoplasmic reticulum when expressed without DUOX1 protein. The expression of this gene or the DUOX1 gene is not suppressed by thyroglobulin (Tg), a macromolecular precursor in thyroid hormone synthesis, while the expression of the DUOX2 and DUOXA2 are significantly suppressed by the Tg. This protein is also a p53-regulated neurogenic factor involved in p53 dependent neuronal differentiation. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2013]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 12 ACMG points.

PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 5 pathogenic variants in the truncated region.
PP5
Variant 15-45117274-C-G is Pathogenic according to our data. Variant chr15-45117274-C-G is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 444.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
DUOXA2NM_207581.4 linkc.738C>G p.Tyr246* stop_gained Exon 5 of 6 ENST00000323030.6 NP_997464.2 Q1HG44-1
DUOXA1NM_001276266.2 linkc.*1832G>C downstream_gene_variant ENST00000560572.6 NP_001263195.1 Q1HG43-1B5M0B7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
DUOXA2ENST00000323030.6 linkc.738C>G p.Tyr246* stop_gained Exon 5 of 6 1 NM_207581.4 ENSP00000319705.5 Q1HG44-1
DUOXA1ENST00000560572.6 linkc.*1832G>C downstream_gene_variant 1 NM_001276266.2 ENSP00000454084.1 Q1HG43-1

Frequencies

GnomAD3 genomes
AF:
0.0000591
AC:
9
AN:
152240
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00154
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.000143
AC:
34
AN:
237622
AF XY:
0.000162
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00186
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000931
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000386
AC:
56
AN:
1451624
Hom.:
0
Cov.:
33
AF XY:
0.0000388
AC XY:
28
AN XY:
720768
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33332
American (AMR)
AF:
0.00
AC:
0
AN:
44270
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25856
East Asian (EAS)
AF:
0.00114
AC:
45
AN:
39476
South Asian (SAS)
AF:
0.0000585
AC:
5
AN:
85482
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
51108
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5678
European-Non Finnish (NFE)
AF:
0.00000181
AC:
2
AN:
1106520
Other (OTH)
AF:
0.0000668
AC:
4
AN:
59902
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.471
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000656
AC:
10
AN:
152358
Hom.:
0
Cov.:
33
AF XY:
0.0000671
AC XY:
5
AN XY:
74498
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41594
American (AMR)
AF:
0.00
AC:
0
AN:
15310
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00174
AC:
9
AN:
5174
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68036
Other (OTH)
AF:
0.000473
AC:
1
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
14
Bravo
AF:
0.0000831
ExAC
AF:
0.000157
AC:
19

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Thyroglobulin synthesis defect Pathogenic:5
Feb 01, 2008
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Mar 14, 2020
Genetics and Genomic Medicine Centre, NeuroGen Healthcare, NeuroGen Healthcare
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Juno Genomics, Hangzhou Juno Genomics, Inc
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PVS1_Strong+PM3_VeryStrong+PP4+PP1 -

Jan 15, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 11, 2023
3billion
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.014%). Predicted Consequence/Location: Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through protein truncation. The predicted truncated protein may be shortened by more than 10%. Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 18042646). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 18042646, 23292166, 25675383, 30110704). The variant has been reported at least twice as pathogenic without evidence for the classification (ClinVar ID: VCV000000444 /PMID: 18042646). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -

Inborn genetic diseases Pathogenic:1
Aug 31, 2021
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.738C>G (p.Y246*) alteration, located in exon 5 (coding exon 5) of the DUOXA2 gene, consists of a C to G substitution at nucleotide position 738. This changes the amino acid from a tyrosine (Y) to a stop codon at amino acid position 246. This alteration occurs at the 3' terminus of the DUOXA2 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 23.4% (75/320 amino acids) of the protein. However, premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). This alteration has been reported in the homozygous state and in trans with a second DUOXA2 mutation in several patients with congenital hypothyroidism (Zamproni, 2008; Yi, 2013; Liu, 2015; Tanase-Nakao, 2018; Jung, 2020). In vitro studies showed reduced protein expression and inability to reconstitute DUOX2 activity, consistent with complete loss of function (Zamproni, 2008). Based on the available evidence, this alteration is classified as pathogenic. -

Familial thyroid dyshormonogenesis Pathogenic:1
Sep 29, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
0.14
D
BayesDel_noAF
Pathogenic
0.42
CADD
Benign
23
DANN
Uncertain
0.98
Eigen
Benign
-0.59
Eigen_PC
Benign
-0.95
FATHMM_MKL
Benign
0.46
N
PhyloP100
-1.8
Vest4
0.81
GERP RS
-2.3
Mutation Taster
=10/190
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4774518; hg19: chr15-45409472; API